RxDoctor Payments Data

Prashant Kumar, MD

Pain Medicine · Worcester, MANPI 1073756441

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,423 of the $6,138 with a category attached, or 88.4%. 24 manufacturers reported payments, led by Boston Scientific at 55.6% of the total. Reporting peaked in 2021 at $1,417 and has fallen 94.5% since, to $77 in 2025.

$6,138in general payments, 2019–2025

Across 236 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Painteq LLC$660
  • SPR Therapeutics, Inc$636
  • Medtronic$291
  • Saluda Medical Americas, Inc.$150
  • Abbott$123
  • plus $865 from 18 others

What the payments were for

  • Travel & lodging$68711%
  • Food & beverage$5,42388%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,138 in reported general payments places this provider in the 75th percentile of 137 pain medicine providers in Massachusetts.

See all pain medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$159,970
Medicare patients
336
Services billed
1,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucyntaTapentadol Hcl49$69,788
Xtampza ErOxycodone Myristate61$53,612
Nucynta ErTapentadol Hcl36$44,275
BelbucaBuprenorphine Hcl35$27,330
OxycontinOxycodone Hcl33$14,880
Gabapentin238$3,006
Buprenorphine13$2,801
Tramadol Hcl ErTramadol Hcl49$2,216
Pregabalin157$1,813
Lidocaine45$1,681
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen103$1,522
Baclofen93$1,388
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen98$1,197
Morphine Sulfate ErMorphine Sulfate60$1,085
Orphenadrine Citrate ErOrphenadrine Citrate23$1,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er, Nucynta Er, Belbuca$116$195,005181 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 137 pain medicine providers in Massachusetts.

Other pain medicine in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →